News Juno halts CAR-T trial again after 2 more deaths Doubts over Juno CAR-T therapy after two more trial deaths.
News Adaptimmune revives ovarian cancer trial T-cell trial will include controversial chemo agent fludarabine.
Views & Analysis Novartis committed to CAR-Ts - but doubts about commercial v... Novartis may have concerns about commercial prospects, says expert.
Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
